AI Model Has Strong Performance for Identifying Pediatric Eye Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 7, 2024 -- An artificial intelligence (AI) model has strong performance for accurately identifying myopia, strabismus, and ptosis using mobile photographs, according to a study published online Aug. 6 in JAMA Network Open.
Qin Shu, M.D., from Shanghai Jiao Tong University School of Medicine, and colleagues developed an AI model to identify myopia, strabismus, and ptosis using mobile photographs in a cross-sectional study. A total of 1,419 images from 476 patients were used to build the model. Of the images, 946 monocular images and 473 binocular images were used to identify myopia and ptosis and to identify strabismus, respectively.
The researchers found that the model demonstrated good sensitivity for detecting myopia, strabismus, and ptosis (0.84, 0.73, and 0.85, respectively). During sex subgroup analysis, the model showed comparable performance in identifying eye disorders in both female and male children. Differences in identifying eye disorders were seen among different age groups.
"The detection model using AI showed strong performance in accurately identifying myopia, strabismus, and ptosis using only smartphone images," the authors write. "These results suggest that it can assist families in screening children for myopia, strabismus, and ptosis, facilitating early identification and reducing the risk of visual function loss and severe problems due to delayed screening."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-08 01:15
Read more
- Two-Fifths of Americans Say They Experience the 'Winter Blues'
- Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death
- Decline Expected in HIV Care Providers in Next Five Years
- Delaying Noncardiac Surgery for Several Months After Heart Attack Found to Be Safer
- Knowledge of Abdominal Aortic Calcification Results Improves Some CVD Risk Factors
- Colonoscopy Still Beats New Blood Tests at Spotting Colon Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions